RAPT
- RAPT Therapeutics, Inc.
()
Overview
Company Summary
RAPT Therapeutics, Inc. is a biopharmaceutical company that focuses on developing novel therapies to address critical unmet needs in the field of immunology and oncology. The company's primary goal is to discover and develop small molecule drugs that modulate the immune system, with the aim of providing transformative treatments for patients with severe diseases.
RAPT's approach is centered around targeting the C-C Motif Chemokine Receptor 4 (CCR4) and the C-C Motif Chemokine Ligand 22 (CCL22), which regulate immune cell trafficking and immune response in various diseases. By selectively inhibiting these molecules, RAPT aims to modulate the immune system, enabling the body to treat diseases more effectively.
The company's lead product candidate, FLX475, is currently being evaluated in clinical trials for cancer indications. FLX475 is an oral small molecule CCR4 antagonist that aims to disrupt the immunosuppressive environment surrounding tumors, allowing the immune system to recognize and kill cancer cells. If successful, FLX475 could potentially revolutionize cancer treatment and offer better outcomes for patients.
RAPT Therapeutics also has a broad pipeline of preclinical candidates targeting various aspects of the immune system, including additional CCR4 compounds and novel immunomodulatory targets. These programs focus on addressing inflammatory and autoimmune diseases, as well as exploring the potential of their therapies in combination with other treatments such as immune checkpoint inhibitors.
In summary, RAPT Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative therapies targeting immune-related diseases, primarily in the areas of oncology and immunology. Through the modulation of immune response and immune cell trafficking, RAPT aims to provide new treatment options for patients with severe diseases where current therapies are inadequate.